ImmBio develops innovative vaccines through key partnerships

The company has selected its portfolio to address major unmet healthcare needs and this approach has attracted a number of partnerships with leading vaccine organisations. In addition to its existing pipeline, ImmBio is interested in pursuing new disease targets, where there is a strong rationale based on the company’s technologies.

In addition ImmBio's ImmBioVax™ technology platform can be applied to the development of cancer vaccines and its relevant IP is available for licensing in Oncology.


For further information on specific partnership opportunities please contact us at: